Mednet Logo
HomeQuestion

How have you incorporated new psoriasis therapies such as deucravacitinib and bimekizumab into your hierarchy of psoriasis treatments?

2
3 Answers
Mednet Member
Mednet Member
Dermatology · Icahn School of Medicine at Mount Sinai (Elmhurst)

I have had good success with both deucravacitinib and bimekizumab and these agents are two welcome additions to our psoriasis treatment arsenal.

For deucravacitinib, ever since I included it in my list of options in treating psoriasis - as an aside, I used to skip over orals due to lack of efficacy ...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Dermatology · Wake Forest University

I’ve begun treating patients with both deucravacitinib and bimekizumab. I tend to prescribe deucravacitinib to patients who prefer oral treatment and who don’t mind the slight herpes simplex/zoster signal associated with the drug. I also use it for patients who have failed multiple biologic treatmen...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Dermatology · University of Pennsylvania Perelman School of Medicine

I have an unusual practice as I treat very severe psoriasis in patients who typically have failed multiple treatments. I've had great success with bimekizumab in some of my hardest-to-treat patients who have failed literally everything else. The question now is, will these patients continue to respo...

Register or Sign In to see full answer